What is the appropriate management for antral gastritis identified during endoscopy?

Management of Antral Gastritis Found During Endoscopy

When antral gastritis is identified during endoscopy, you must obtain biopsies from both the antrum and gastric body in separate jars for histopathological confirmation, test for H. pylori infection, and eradicate it if present. 1

Immediate Endoscopic Actions

Biopsy Protocol

• Obtain biopsies from the antrum/incisura AND gastric body/corpus, placing them in separately labeled specimen jars 1
• This topographic separation is essential because antral-predominant gastritis suggests H. pylori-associated atrophic gastritis (HpAG), while corpus-predominant disease with antral sparing indicates autoimmune gastritis (AIG) 1
• Target any additional mucosal abnormalities with separate biopsies 1
• The separate jar protocol enables proper risk stratification using OLGA/OLGIM staging systems 1

Recognize Endoscopic Features

Look for subtle signs of atrophic changes: 1

• Pale appearance of gastric mucosa
• Increased visibility of submucosal vasculature (due to mucosal thinning)
• Loss or flattening of gastric folds
• Light blue crests and white opaque fields (if intestinal metaplasia present)

Post-Endoscopy Management Algorithm

Step 1: Test for H. pylori

All patients with antral gastritis must be assessed for H. pylori infection 1

• Use biopsy-based testing (histology, rapid urease test) or non-invasive methods (stool antigen, urea breath test)
• Avoid serological testing for diagnosis as it cannot distinguish active from past infection 1

Step 2: If H. pylori Positive

Treat with eradication therapy and confirm successful eradication 1

• First-line empiric therapy: Bismuth quadruple therapy for 14 days 2
• Alternative: Rifabutin triple therapy or potassium-competitive acid blocker dual therapy for 14 days (if no penicillin allergy) 2
• Confirm eradication using non-serological testing at least 4 weeks after completing therapy 1, 2
• H. pylori eradication is critical because it can halt or slow progression of the atrophic cascade toward gastric cancer 1, 3

Step 3: Evaluate for Nutritional Deficiencies

Screen for iron and vitamin B-12 deficiencies, especially if corpus involvement is present 1

• These deficiencies occur due to loss of gastric acid and intrinsic factor production 1
• Replace deficiencies as needed with appropriate supplementation 1

Step 4: Determine Surveillance Strategy Based on Histology

If Non-Atrophic Gastritis Only

• No specific surveillance required after H. pylori eradication 3
• Focus on confirming eradication and symptom resolution

If Atrophic Gastritis or Intestinal Metaplasia Present

The presence of intestinal metaplasia on histology almost invariably implies atrophic gastritis 1

For advanced atrophic gastritis (extensive anatomic distribution and/or severe histologic grade): surveillance endoscopy every 3 years 1

• "Advanced" is defined by extent (multifocal involvement) and severity (marked glandular loss) 1
• Risk stratification should incorporate OLGA/OLGIM staging when available 1
• Surveillance intervals may be individualized based on additional risk factors (family history, ethnicity, incomplete intestinal metaplasia subtype) 3

If Corpus-Predominant Pattern with Antral Sparing

This suggests autoimmune gastritis rather than H. pylori-associated disease 1

Additional workup required: 1

• Check antiparietal cell antibodies and anti-intrinsic factor antibodies
• Screen for vitamin B-12 and iron deficiency (higher risk than HpAG)
• Screen for autoimmune thyroid disease 1
• Surveillance for type 1 gastric neuroendocrine tumors every 1-2 years 1

Critical Pitfalls to Avoid

Do not rely on endoscopic appearance alone - atrophic changes are often subtle and require histopathological confirmation 1

Do not place antral and corpus biopsies in the same jar - this prevents accurate topographic assessment and risk stratification 1

Do not use serological H. pylori testing for post-treatment confirmation - serology remains positive for years after eradication 1

Do not assume antral gastritis is benign - it represents the initial stage of the gastric cancer precursor cascade in H. pylori infection, with atrophic changes beginning in the antrum/incisura before spreading to the corpus 1

If antral atrophy is seen in a corpus-predominant pattern, consider concomitant H. pylori infection - this overlap occurs and requires testing/treatment 1

Quality of Life Considerations

Eradicating H. pylori and preventing progression to gastric cancer directly impacts mortality 1, 3. The extensive atrophy and metaplasia associated with increased cancer risk can be halted or reversed with early H. pylori treatment 1. Nutritional deficiencies, if left untreated, significantly impair quality of life through anemia-related fatigue and neurological complications 1.